Laura Huppert, MD, and Yara Abdou, MD, discuss the CAPItello-291 trial which looked at the efficacy of capivasertib, a small molecule AKT inhibitor, in combination with fulvestrant for patients with estrogen receptor positive, HER2 negative advanced breast cancer who had progressed on prior endocrine therapy.
Related Keywords
Yara Abdou , Laura Huppert , , Emerging Therapies , Breast Cancer , Evaluating Capivasertib Plus Fulvestrant , Patients With , Metastatic Breast Cancer , Mbc , Abc , Breast Cancer Treatments , Breast Cancer Therapies , Metastatic Breast Cancer Treatments ,
vimarsana.com © 2020. All Rights Reserved.